Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alkermes plc (ALKS) SEC filings page on Stock Titan brings together the companys regulatory disclosures from the U.S. Securities and Exchange Commission, offering structured access to its Forms 8-K and other key documents. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline that includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia.
Through its current reports on Form 8-K, Alkermes provides official details on material events. These include financial result announcements, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, along with updates to its annual financial expectations. Such filings often include reconciliations of non-GAAP measures like EBITDA and adjusted EBITDA and discuss revenue contributions from proprietary products and manufacturing and royalty arrangements.
Alkermes also uses Form 8-K to disclose clinical and regulatory milestones, such as positive topline results from phase 2 studies of alixorexton in narcolepsy type 1 and type 2, and to furnish related investor presentations. These documents help readers understand the design, endpoints and topline outcomes of the Vibrance studies and the companys plans for further development.
Another important category of filings relates to transaction agreements and financing. Alkermes has filed a transaction agreement and an amendment describing the terms under which it proposes to acquire Avadel Pharmaceuticals plc, including cash consideration per share and a non-transferable contingent value right linked to a potential regulatory milestone for LUMRYZ. The company has also filed an amended and restated bridge term loan credit agreement, outlining a senior secured bridge term loan facility intended to support financing of the proposed acquisition, along with associated covenants and security arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as earnings updates, clinical trial disclosures, transaction terms and new financing commitments. Real-time updates from EDGAR allow investors to see new ALKS filings as they appear, while structured access to exhibits makes it easier to review detailed agreements, credit facilities and presentation materials.
For those tracking insider and governance information, Alkermes broader SEC reporting framework also encompasses ownership and compensation disclosures in its periodic and proxy filings, which can be accessed alongside 8-Ks. Together, these documents form a detailed record of Alkermes financial condition, strategic transactions, development progress and capital structure.
Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units and ordinary shares. On 2026-02-26, he exercised 5,410 restricted stock units, which converted into 5,410 ordinary shares at a stated price of $0.0000 per share.
A related Form 4 line shows 2,403 ordinary shares disposed of at $30.73 per share in a code F transaction, which reflects shares withheld to satisfy tax obligations rather than an open-market sale. After these transactions, Nichols directly owned 115,769 ordinary shares and held 10,819 restricted stock units, each representing a contingent right to receive one ordinary share. The restricted stock unit award vests in four equal annual installments beginning on 02/26/2025.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity compensation-related transactions. On February 26, 2026, he acquired 8,322 ordinary shares upon the exercise of a restricted stock unit award, with each unit representing one ordinary share. On the same date, 3,695 ordinary shares were disposed of at $30.73 per share to satisfy tax withholding obligations. Following these transactions, Curtis directly owned 241,308 ordinary shares. The underlying restricted stock units vest in four equal annual installments beginning on February 26, 2025.
Alkermes plc executive Craig C. Hopkinson reported equity award activity involving restricted stock units and ordinary shares. On 2/26/2026, he exercised 6,866 restricted stock units, which converted into 6,866 ordinary shares at a stated price of $0.0000 per share. In a related tax-withholding transaction, 3,049 ordinary shares were disposed of at $30.73 per share to cover tax obligations rather than as an open-market sale. Following these transactions, he directly held 93,389 ordinary shares and 13,732 restricted stock units. Each restricted stock unit represents a contingent right to receive one ordinary share and the award vests in four equal annual installments commencing on 02/26/2025.
Alkermes plc executive David Joseph Gaffin reported equity award activity. On 2/26/2026, he acquired 6,866 restricted stock units and 6,866 ordinary shares through an exercise or conversion of derivative securities. A separate transaction disposed of 3,049 ordinary shares at $30.73 per share to satisfy tax obligations.
After these transactions, Gaffin directly held 13,732 restricted stock units and 239,694 ordinary shares. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments beginning on 2/26/2025.
Alkermes plc VP Samuel Joseph Parisi reported equity award activity. On 2/23/2026, 2,283 restricted stock units were exercised or converted into 2,283 ordinary shares at a price of $0.00 per share. A separate transaction disposed of 672 ordinary shares at $32.19 per share to cover tax withholding obligations. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments starting on 2/23/2024. After these transactions, he directly held 2,284 restricted stock units and 12,668 ordinary shares.
Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported equity compensation activity involving restricted stock units and ordinary shares. On 2/23/2026, 6,407 restricted stock units were exercised into 6,407 ordinary shares at a price of $0.00 per share, reflecting a derivative exercise or conversion. To cover tax obligations, 2,845 ordinary shares were disposed of at $32.19 per share through a tax-withholding transaction. After these movements, Nichols directly owned 112,762 ordinary shares. Each restricted stock unit represents a right to receive one ordinary share, and units vest in four equal annual installments beginning 2/23/2024.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity transactions on 2/23/2026. He exercised a restricted stock unit award, converting 8,738 restricted stock units into 8,738 ordinary shares at a stated price of $0.0000 per share.
To cover tax obligations related to this equity compensation, 3,880 ordinary shares were disposed of in a tax-withholding transaction at $32.1900 per share. After these transactions, Curtis directly owned 236,681 ordinary shares. Each restricted stock unit represents one ordinary share and vests in four equal annual installments beginning on 2/23/2024.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised 7,689 restricted stock units into ordinary shares on February 23, 2026, with each unit converting into one share. On the same date, 3,414 ordinary shares at $32.19 per share were withheld to cover tax obligations, leaving him with 89,572 ordinary shares held directly. The restricted stock unit award vests in four equal annual installments beginning on February 23, 2024.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported equity award activity involving restricted stock units and ordinary shares. On February 23, 2026, 7,689 restricted stock units were exercised or converted at $0.00 per unit into 7,689 ordinary shares, increasing his directly held ordinary shares to 239,291 before a related tax transaction. In a separate transaction the same day, 3,414 ordinary shares were disposed of at $32.19 per share to cover tax withholding, leaving him with 235,877 directly owned ordinary shares. Each restricted stock unit represents one ordinary share, and the award vests in four equal annual installments beginning on February 23, 2024.
Alkermes plc announced a planned CEO transition. Long‑time Chief Executive Officer Richard F. Pops will retire from the CEO role effective July 31, 2026, after about 35 years, and will remain non‑executive Chairman while serving as Senior Advisor through December 31, 2026.
Executive Vice President and Chief Operating Officer Blair C. Jackson has been appointed to become CEO effective August 1, 2026. Jackson has more than two decades at Alkermes in scientific, operational and strategic roles and previously served as interim principal financial officer.
Under a letter agreement, Pops will receive a $75,000 monthly cash retainer as Senior Advisor, a fiscal 2026 cash bonus at target level prorated for his CEO service, and a 2026 time‑based restricted stock unit award with a grant value of $2,687,500, prorated to reflect service through the Senior Advisor term and scheduled to vest on December 31, 2026. He will also receive a prorated $40,000 annual retainer for his service as non‑executive Chairman, continued vesting of existing equity awards under specified post‑service terms, and reimbursement of up to $60,000 in legal fees related to the transition.